We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current RGEN market cap is 7.09B. The company's latest EPS is USD 0.7455 and P/E is 168.50.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 182.66M | 159.17M | 172.46M | 155.05M | 151.35M |
| Operating Income | 31.26M | 19.4M | 1.78M | -887k | 2.03M |
| Net Income | 28.83M | 20.06M | 18.17M | -25.49M | 2.09M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 270.25M | 366.26M | 670.53M | 830.27M | 669.33M |
| Operating Income | 36.08M | 69.82M | 167.25M | 224.67M | 54.58M |
| Net Income | 21.41M | 59.93M | 128.29M | 185.96M | 41.58M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 2.54B | 2.55B | 2.51B | 2.82B | 2.85B |
| Total Liabilities | 597.74M | 578.08M | 525.57M | 853.21M | 878.67M |
| Total Equity | 1.94B | 1.97B | 1.99B | 1.97B | 1.97B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 1.4B | 1.9B | 2.36B | 2.52B | 2.82B |
| Total Liabilities | 340.35M | 373.74M | 608.29M | 613.96M | 853.21M |
| Total Equity | 1.06B | 1.53B | 1.75B | 1.91B | 1.97B |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 11.15M | 45.62M | 84.85M | 113.92M | 44.71M |
| Investing | -9.43M | 55.4M | 46.63M | -123.28M | -8.36M |
| Financing | -9.56M | -18.39M | -19.17M | 248.96M | -8.97M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 67.22M | 62.63M | 119.02M | 172.08M | 113.92M |
| Investing | -205.31M | -201.39M | -221.17M | -233.24M | -123.28M |
| Financing | 484.87M | 305.92M | 961k | -13.34M | 248.96M |
| Market Cap | 7.09B |
| Price to Earnings Ratio | 168.50 |
| Price to Sales Ratio | 10.47 |
| Price to Cash Ratio | 9.32 |
| Price to Book Ratio | 3.55 |
| Dividend Yield | - |
| Shares Outstanding | 55.77M |
| Average Volume (1 week) | 969.5k |
| Average Volume (1 Month) | 624.3k |
| 52 Week Change | -23.26% |
| 52 Week High | 211.13 |
| 52 Week Low | 110.45 |
| Spread (Intraday) | 32.5 (20.3%) |
| Company Name | Repligen Corp |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.repligen.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
